You are here

oncology

Pfizer, Merck, J&J well-positioned for M&A and Biogen and BioMarin are prime targets: report

Pfizer, Merck, J&J well-positioned for M&A and Biogen and BioMarin are prime targets: report

Fierce Pharma

Flag link:

2 Pharma Stocks in the Middle of an Oncology Sales Explosion

2 Pharma Stocks in the Middle of an Oncology Sales Explosion

Motley Fool

Flag link:

Sanofi’s latest R&D remodeling spotlights what’s hot (bispecifics) and what’s not (CTLA-4) in oncology today

Sanofi’s latest R&D remodeling spotlights what’s hot (bispecifics) and what’s not (CTLA-4) in oncology today

Endpoints

Flag link:

Oncology round-up: CAR-T conference raises hopes for solid tumour therapy

Oncology round-up: CAR-T conference raises hopes for solid tumour therapy

Pharmaforum

Flag link:

Pfizer’s Cancer Portfolio Expected to Rake in $8.3 Billion in 2019

Pfizer’s Cancer Portfolio Expected to Rake in $8.3 Billion in 2019

BioSpace

Flag link:

A two-fisted punch against cancer metastasis

A two-fisted punch against cancer metastasis

Fierce Biotech

Duke University

Flag link:

GSK closes acquisition of Tesaro for $5.1bn

GSK closes acquisition of Tesaro for $5.1bn

Pharmaceutical Business Review

Flag link:

ADC doses first patient in phase I trial of ADCT-601 in advanced solid tumors

ADC doses first patient in phase I trial of ADCT-601 in advanced solid tumors

Pharmaceutical Business Review

ADC Therapeutics

clinical trials

Flag link:

AstraZeneca rejigs commercial ranks around cancer, biopharma in wake of Mallon's departure

AstraZeneca rejigs commercial ranks around cancer, biopharma in wake of Mallon's departure

Fierce Pharma

Flag link:

Pfizer, Merck shares smoking hot in 2018 despite doldrums for overall biopharma sector

Pfizer, Merck shares smoking hot in 2018 despite doldrums for overall biopharma sector

Fierce Pharma

Flag link:

Novartis oncology CEO quits after less than a year

Novartis oncology CEO quits after less than a year

Pharmaforum

Susanne Schaffert

Flag link:

Auron and Elucidata Launch AI Driven Collaboration to Identify Targets for Differentiation-Based Oncology Therapies

Auron and Elucidata Launch AI Driven Collaboration to Identify Targets for Differentiation-Based Oncology Therapies

CP WIre

artificial intelligence

Auron Therapeutics

Flag link:

Merck taps Roche for Keytruda companion diagnostic

Merck taps Roche for Keytruda companion diagnostic

Medtech Dive

companion diagnostics

Flag link:

Amgen Contributes to Nonprofit to Support Greater Diversity in Clinical Trials

Amgen Contributes to Nonprofit to Support Greater Diversity in Clinical Trials

BioSpace

clinical trials

Flag link:

Pfizer to add 100 oncology R&D jobs, cut others amid restructure

Pfizer to add 100 oncology R&D jobs, cut others amid restructure

Biopharma Dive

Flag link:

FDA Drafts Guidance on Oncology Companion Diagnostics

FDA Drafts Guidance on Oncology Companion Diagnostics

RAPS.org

cancer companion diagnostics

Flag link:

All in: Novartis adds another drug to its fast-growing radiopharmaceuticals division

All in: Novartis adds another drug to its fast-growing radiopharmaceuticals division

Endpoints

radiopharmaceuticals

Fujifilm Toyama

Advanced Accelerator Application

Flag link:

Shattering an old record, FDA quickly OKs pioneering, site-agnostic cancer drug larotrectinib from Loxo and Bayer

Shattering an old record, FDA quickly OKs pioneering, site-agnostic cancer drug larotrectinib from Loxo and Bayer

Endpoints

personalized medicine

Flag link:

Drugmakers Seek Clarity on Guidance on Use of Placebo and Blinding in Oncology Trials

Drugmakers Seek Clarity on Guidance on Use of Placebo and Blinding in Oncology Trials

RAPS.org

clinical trials

Flag link:

AstraZeneca gets rights, options to basket of next-gen immuno-oncology therapies from Innate

AstraZeneca gets rights, options to basket of next-gen immuno-oncology therapies from Innate

BioCentury

Flag link:

Pages